Save Mart to use MirixaEdge in employee health-and-wellness initiative
RESTON, Va. A regional supermarket chain with 244 stores in California and Nevada has selected Mirixa’s Web-based clinical application for the delivery of medication therapy management services as an integral part of its employee health-and-wellness initiative.
Save Mart said MirixaEdge — which will be deployed to Save Mart Supermarkets’ 115 in-store pharmacies by May — will encourage employees to play an active role in their medication therapy management and develop patient medication records with the help of vital information providing by the application. In addition to medication therapy management, MirixaEdge includes patient care program templates for such chronic conditions as asthma, diabetes and cardiovascular disease. These templates help to guide the pharmacist through the data collection process for illnesses that typically involve multiple medications and coexisting conditions, Save Mart said.
“Our company believes that our employees are a vital company asset and their well-being is of paramount importance,” said Michele Snider, executive director pharmacy at Save Mart. “We want to empower our employees and actively engage them in the management of their health and wellness. MirixaEdge will enable our pharmacists to consult directly with employees and to help them to understand why they are prescribed specific medications and why they should take the medications as prescribed.”
Upsher-Smith inks deal with Proximagen for tonabersat
MAPLE GROVE, Minn. Upsher-Smith Labs has acquired exclusive North American rights for an investigational drug designed to treat such conditions as migraine and epilepsy, the drug maker announced Monday.
Under the deal, with Proximagen Neuroscience, Upsher-Smith will be responsible for development, regulatory filing and commercialization activities for the drug tonabersat in the North American market.
“This agreement supports our strategic vision of building a leadership position in the central nervous system field,” Upsher-Smith president Mark Evenstad said. “We are excited about our growing [central nervous system] development portfolio that we hope will provide benefit to patients suffering from neurologic conditions.”
The company is also developing USL255, a once-daily formulation of the generic drug topiramate. The drug is in phase 3 trials as a treatment for epilepsy. Johnson & Johnson originally marketed topiramate under the brand name Topamax.
Vaccines with two strains of influenza may be more effective in children, research team says
ST. LOUIS Vaccines likely would work better in protecting children from flu if they included both strains of influenza B instead of just one, a St. Louis University press report stated last week, citing research conducted through its Center for Vaccine Development.
"Adding a second influenza B virus strain to the seasonal influenza vaccine would take some of the guesswork out of strain selection and help improve the vaccine’s ability to prevent influenza," stated Robert Belshe, lead investigator and director of the center. "Since in five of the last 10 years, the influenza B component in the vaccine has been the incorrect one, this seems like an obvious advance to me."
Every spring, scientists predict which strain of influenza will be circulating in the community the following fall. Historically, they choose two different subtypes of influenza A and one of influenza B.
Research findings in the March issue of Vaccine highlight the importance of adding both lines of influenza B into the vaccine to better protect against the flu, Belshe noted.
The research team examined how well current vaccines protect against influenza B by looking at the immune response of ferrets that were given FluMist, a live attenuated influenza vaccine manufactured by MedImmune.
When ferrets were vaccinated against influenza, the ferrets that were exposed to a strain of influenza B virus that did not match what was in the vaccine didn’t have a strong antibody response. However they had a vigorous antibody response when given a vaccine that contained both strains of influenza B.
This showed that immunizing against one strain of influenza B does not appear to protect against the other strain and that a vaccine containing both influenza B strains is likely to offer greater protection from flu.
"These data highlight the need for vaccination strategies that provide enhanced protection against both lineages of influenza B," Belshe said.
The study was sponsored by MedImmune. Belshe has served as a consultant and as part of the speakers bureau for MedImmune and other study authors are MedImmune employees.